Chocron, E.S., Munkácsy, E., Kim, H.S., Karpowicz, P., Jiang, N., Van Skike, C.E., DeRosa, N., Banh, A.Q., Palavicini, J.P., Wityk, P., Kalinowski, L., Galvan, V., Osmulski, P.A., Jankowska, E., Gaczynska, M., Pickering, A.M. (2022). Genetic and pharmacologic proteasome augmentation ameliorates Alzheimer's-like pathology in mouse and fly APP overexpression models.  Sci. Adv. 8(23): eabk2252.

FBrf0253730

Research paper

The proteasome has key roles in neuronal proteostasis, including the removal of misfolded and oxidized proteins, presynaptic protein turnover, and synaptic efficacy and plasticity. Proteasome dysfunction is a prominent feature of Alzheimer's disease (AD). We show that prevention of proteasome dysfunction by genetic manipulation delays mortality, cell death, and cognitive deficits in fly and cell culture AD models. We developed a transgenic mouse with neuronal-specific proteasome overexpression that, when crossed with an AD mouse model, showed reduced mortality and cognitive deficits. To establish translational relevance, we developed a set of TAT-based proteasome-activating peptidomimetics that stably penetrated the blood-brain barrier and enhanced 20S/26S proteasome activity. These agonists protected against cell death, cognitive decline, and mortality in cell culture, fly, and mouse AD models. The protective effects of proteasome overexpression appear to be driven, at least in part, by the proteasome's increased turnover of the amyloid precursor protein along with the prevention of overall proteostatic dysfunction.

PMC9177073 (PMC) (EuropePMC)